Meningococcal Vaccination Rates Among People With a New Diagnosis of HIV Infection in the US

Ghaswalla, Parinaz; Marshall, Gary S.; Bengtson, Lindsay G.S.; Buikema, Ami; Bancroft, T. A.; Koep, Eleena; Novy, Patricia; Hogea, Cosmina

doi:10.1001/jamanetworkopen.2022.8573

Cited by 10 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these limitations, this study adds to the literature by providing an analysis of large numbers of adults in the US. Claims data are utilized often in vaccination administration studies, and the longitudinal information with dates of health care utilization allowed us to identify the exact timing of HPV vaccine administration and avoid biases related to self-report.…”

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Vaccine Administration Trends Among Commercially Insured US Adults Aged 27-45 Years Before and After Advisory Committee on Immunization Practices Recommendation Change, 2007-2020

et al. 2022

View full text Add to dashboard Cite

ImportanceIn 2019, the Advisory Committee on Immunization Practices (ACIP) recommended patient-clinician shared decision-making for human papillomavirus (HPV) vaccination in adults aged 27 to 45 years. Less is known about the HPV vaccine administration trends in this age group before and after this recommendation update.ObjectiveTo examine the association between the ACIP recommendation update and the HPV vaccine administration among US adults aged 27 to 45 years.Design, Setting, and ParticipantsThis large commercial claim-based retrospective cohort study used the Optum Clinformatics database for validated claims from January 1, 2007, through December 31, 2020. A total of 22 600 520 US adults aged 27 to 45 years without previous HPV vaccination claims during the study and enrollment period were included.Main Outcomes and MeasuresThe first-appearing HPV vaccination claim per individual was defined as a new HPV vaccine administration. Interrupted time-series analyses were conducted to assess the association between the ACIP update and the quarterly vaccine administration rate change. The annual rate trends across race and ethnicity groups and the proportions of vaccination cases by sub–age groups and valent types were also estimated. Vaccine administration trends were assessed by race and ethnicity in this age group because HPV vaccination trends were found to differ by race and ethnicity in the initially eligible population.ResultsAmong 22 600 520 final study participants, the majority were men (50.9%) and non-Hispanic White (53.4%), and the mean (SD) age when first observed was 34.6 (5.8) years. In women, the ACIP update was associated with an immediate increase in vaccine administration rate (coefficient β2, 40.18 per 100 000 persons; P = .01) and an increased slope (coefficient β3, 9.62 per 100 000 persons per quarter; P = .03) over time postupdate. The ACIP update was only associated with an immediate increase in vaccine administration in men (coefficient β2, 27.54; P &lt; .001). The annual rate trends were similar across race and ethnicity groups. Age at vaccine administration shifted over time (eg, women aged 40-45 years comprised only 4.9% of vaccinations in 2017, then 19.0% in 2019, and 22.7% in 2020). The most administered HPV vaccines in 2020 were 9 valent (women, 97.0%; men, 97.7%).Conclusions and RelevanceIn this population-based cohort study, there were statistically significant increases in HPV vaccine administration in adults aged 27 to 45 years after the ACIP recommendation update. Patient-clinician shared decision-making may have been the main associated factor for this increase. Further research is warranted to explore the decision-making process in receiving HPV vaccination and to develop effective decision aids to maximize the cancer prevention benefit in this age group.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Vaccine Administration Trends Among Commercially Insured US Adults Aged 27-45 Years Before and After Advisory Committee on Immunization Practices Recommendation Change, 2007-2020

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The provision of LGBT inclusivity training for healthcare providers may help to encourage such disclosure, given this study and others [ 30 , 31 ] have identified a lack of LGBT cultural competency in the Inland Empire region. Healthcare provider education focused on vaccine recommendations for MSM will likely also be important for encouraging providers to discuss HPV and meningococcal vaccines with their eligible patients [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Barriers and facilitators to HPV and meningococcal vaccination among men who have sex with men: a qualitative study

Naidu

Polonijo

2023

BMC Public Health

View full text Add to dashboard Cite

Background Men who have sex with men (MSM) have suboptimal uptake of human papillomavirus (HPV) and meningococcal vaccines. This study examines barriers and facilitators to HPV and meningococcal vaccination among MSM in a large, racially/ethnically diverse, and medically underserved U.S. region. Methods In 2020, we conducted five focus groups with MSM living in the Inland Empire, California. Participants discussed (1) their knowledge about and attitudes toward HPV, meningococcal disease, and related vaccines; and (2) factors that would encourage or discourage vaccine uptake. Data were systematically analyzed to identify salient barriers and facilitators to vaccination. Results Participants (N = 25) had a median age of 29. Most were Hispanic (68%), self-identified as gay (84%), and had college degrees (64%). Key barriers to vaccination included: (1) limited awareness and knowledge about HPV and meningococcal disease, (2) reliance on mainstream healthcare providers for vaccine information, (3) stigma and reluctance to disclose sexual orientation, (4) uncertainty about health insurance coverage and vaccine costs, and (5) distance and time required to access vaccines. Key facilitators to vaccination were: (1) vaccine confidence, (2) perceived severity of HPV and meningococcal disease, (3) bundling vaccination into routine healthcare, and (4) pharmacies as vaccination sites. Conclusions Findings highlight opportunities for HPV and meningococcal vaccine promotion, including targeted education and awareness campaigns for MSM, LGBT inclusivity training for healthcare providers, and structural interventions to improve vaccine accessibility.

show abstract

“…For individuals newly diagnosed with HIV, in a cohort study using US commercial claims, only 16.3% of individuals eligible for vaccination received a first dose of the MenACWY vaccine in the 2 years after an HIV diagnosis [ 15 ]. Also, among those individuals who received a first dose and had at least 1 year of continuous enrollment after the first dose, only 66.2% received a second dose within 1 year of the first dose [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…We know the majority of vaccinations occur in a medical setting, where notable differences exist between provider types regarding the frequency of immunizing individuals at increased risk [ 13 – 15 ]. Therefore, medical education for healthcare providers and patients needs to be tailored to particular provider situations.…”

Section: Discussionmentioning

confidence: 99%

Expert Perspectives on the Vaccination of Individuals Who Are at Increased Risk of Meningococcal Disease Due to Medical Conditions: A Podcast

et al. 2023

Self Cite

View full text Add to dashboard Cite

Patients with functional or anatomic asplenia, including sickle cell anemia; complement component deficiency; or human immunodeficiency virus (HIV) infection have a significantly increased risk of developing meningococcal disease. The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommends vaccination with a quadrivalent meningococcal conjugate vaccine against serogroups A, C, W, and Y (MenACWY) for individuals 2 months of age or older who are diagnosed with functional or anatomic asplenia, complement component deficiency, or HIV infection. Vaccination with a meningococcal vaccine against serogroup B (MenB) is also recommended for individuals 10 years of age or older who are diagnosed with functional or anatomic asplenia or complement component deficiency. Despite these recommendations, recent studies have shown that vaccination coverage in these populations is low. In this podcast, the authors discuss the challenges for implementing vaccine recommendations for individuals with medical conditions at increased risk of developing meningococcal disease and discuss strategies to increase coverage. Suboptimal vaccination rates could be addressed by better educating healthcare providers about recommendations for MenACWY and MenB vaccines in individuals at increased risk, increasing awareness of low vaccination coverage, and tailoring the education to the needs of particular healthcare providers and their respective patient populations. Barriers to vaccination could also be removed by administering vaccines at alternative sites of care, bundling preventative services, and implementing vaccination reminder systems that are tied to immunization information systems. Electronic supplementary material The online version of this article (10.1007/s40121-023-00778-1) contains supplementary material, which is available to authorized users.

show abstract

Meningococcal Vaccination Rates Among People With a New Diagnosis of HIV Infection in the US

Cited by 10 publications

References 20 publications

Human Papillomavirus Vaccine Administration Trends Among Commercially Insured US Adults Aged 27-45 Years Before and After Advisory Committee on Immunization Practices Recommendation Change, 2007-2020

Human Papillomavirus Vaccine Administration Trends Among Commercially Insured US Adults Aged 27-45 Years Before and After Advisory Committee on Immunization Practices Recommendation Change, 2007-2020

Barriers and facilitators to HPV and meningococcal vaccination among men who have sex with men: a qualitative study

Expert Perspectives on the Vaccination of Individuals Who Are at Increased Risk of Meningococcal Disease Due to Medical Conditions: A Podcast

Contact Info

Product

Resources

About